Supplementary figure legends

Supplementary Figure 1. Induction of lagging chromatids or chromatid bridges at anaphase by H_2O_2 in HCT116 cells. Asterisks indicate significant differences as compared to the control [t-test, P < 0.05 (*), 0.01 (**), and 0.001 (***)]. A, Lagging chromatids at anaphase in a HCT116 cell 4 h after H_2O_2 treatment. Bar, 10 µm. B, H_2O_2 -induced aberrant anaphase cells with lagging chromosomes and/or chromosome bridges in HCT116 cells. Cells grown on a chamber slide were treated with H_2O_2 for 30 min and grown for 4 to 6 h. C, Induction of aneuploidy by H_2O_2 in HCT116 cells. Cells were treated with H_2O_2 for 30 min and grown for two cell cycles. The background chromosome number is 45 in HCT116 cells. Therefore cells not containing 45 chromosomes are considered aneuploid cells.

Supplementary Figure 2. H_2O_2 -induced chromosomal aberrations in thymocytes. Nonirradiated thymocytes (5 x 10⁶ cells per dish) were cultured with the proliferation stimuli for 24 h at 37°C, treated with H_2O_2 for 1 h, and then cultured with catalase for 31 h. Open circles denote individual mouse data. Closed circles with error bars denote the mean values \pm standard deviations.

Supplementary Figure 3. Examples of karyotypic changes detected by chromosome painting in thymocytes and resultant thymic lymphomas. A, 10w-1 thymocyte painted with probes for chromosomes 8-14. Arrows indicate t(2;12). Chromosome 2 was not painted in this figure. B, The same translocation was observed in 10w-1-2 thymic lymphoma derived from 10w-1 thymocytes. In A and B, cells possessed trisomy 15, but chromosome 15 was not painted in these figures. C, 10w-7 thymocyte painted with probes for chromosomes 15-Y. Arrow indicates isochromosome 15. D, The same isochromosome 15 was detected in 10w-7-1 thymic lymphoma derived from 10w-7 thymocytes. In C and D, cells also bore t(1;12), but t(1;12) was not detected in these figures.





10w-1 thymocyte 41, +15, t(2;12)



10w-1-2 thymic lymphoma



probe: chromosomes 8-14

10w-7 thymocyte 40, i(15), t(1;12)



10w-7-1 thymic lymphoma



probe: chromosomes 15-Y

Time after irradiation	No. of thymocytes (mice) examined	% aneuploid cells	No. of cells with different chromosome number											
	()		38 (%)	39 (%)	40 (%)	41 (%)	42 (%)	43 (%)	44 (%)	45 (%)	46 (%)	47 (%)	48 (%)	49 (%)
Nonirradiated	200 (5)	0.5			199 (99.5)	1 (0.5)								
0 week (2 h)	200 (5)	3.0	1 (0.5)	3 (1.5)	194 (97)	(1)								
2 weeks	360 (9)	14.4	(010)	9 (2.5)	308 (86)	36 (10)	7 (2)							
4 weeks	320 (8)	34.1	1 (0.3)	(2.6) 2 (0.6)	211	101 (32)	(-) 4 (1)	$\begin{pmatrix} 1 \\ (0,3) \end{pmatrix}$						
6 weeks	360 (9)	34.7	(0,0) 3 (1)	8 (2)	235 (65)	(31)	(1) 2 (0.6)	(0.0)						
8 weeks	600 (15)	28.3	(1)	(-) 11 (2)	429 (72)	146 (24)	12 (2)	1 (0.2)	1 (0.2)					
10 weeks	280 (7)	18.9		(-) 8 (3)	227 (81)	(16)	(0.4)	(**_)	(**=)					
13 weeks	320 (8)	33.1		8 (3)	214 (67)	72 (23)	26 (8)							
Thymic lymphomas	560 (14)	61.6		2 (0.4)	215 (38)	286 (51)	10 (2)	6 (1)	0 (0)	0 (0)	0 (0)	3 (0.5)	24 (4)	14 (3)

Supplementary Table 1. An euploidy in post-irradiation thymocytes and thymic lymphomas.

Mice ^a	Treatments of thymocytes	No. of metaphases examined	Aneuploid cells (%)	No. of metaphase cells with different chromosome number					
				39	40	41	42		
13w-6	Colcemid, 3 h	40	2 (5.0)	0	38	2	0		
	PMA, 48 h	40	2 (5.0)	0	38	2	0		
13w-7	Colcemid, 3 h	40	28 (70.0)	0	12	26	2		
	PMA, 48 h	40	27 (67.5)	1	13	26	0		
13w-9	Colcemid, 3 h	40	12 (30.0)	0	28	12	0		
	PMA, 48 h	40	15 (37.5)	0	25	15	0		
13w-10	Colcemid, 3 h	40	28 (70.0)	0	12	3	25		
	PMA, 48 h	40	27 (67.5)	0	13	1	26		
13w-11	Colcemid, 3 h	40	10 (25.0)	0	30	10	0		
	PMA, 48 h	40	13 (32.5)	3	27	10	0		
13w-12	Colcemid, 3 h	40	0 (0)	0	40	0	0		
	PMA, 48 h	40	1 (2.5)	1	39	0	0		
13w-14	Colcemid, 3 h	40	18 (45.0)	2	22	16	0		
	PMA, 48 h	40	22 (55.0)	0	18	22	0		
13w-15	Colcemid, 3 h	40	2 (5.0)	0	38	2	0		
	PMA, 48 h	40	1 (2.5)	0	39	1	0		

Supplementary Table 2. Comparison of percent aneupoidy between thymocytes incubated with Colcemid for 3 h and thymocytes cultured with PMA, ionomycin, and 2-mercaptoethanol for 48 h.

^a Mice were irradiated at 1.8 Gy 4 times at 1-week intervals. Aneuploidy was examined in thymocytes 13 weeks after irradiation.

Weeks after irradiation	No. of cells (mice)	No. of aberrant cells	Mean No. of aberrations	Chro	omatid	-type		Chr	omosoi	ne-type					
	examined	(%)	per cell	G	В	Е	SM	G	В	Dic	R	F	DM	Pul	CF
Nonirradiated	1912 (10)	126 (6.6)	0.069	103	12	7	0	2	0	0	0	0	1	1	6
0	353 (5)	145 (41.1)	0.808	38	12	14	6	1	0	83	16	122	14	2	5
2	1000 (5)	102 (10.2)	0.113	60	6	6	3	7	0	7	0	2	5	1	16
4	1000 (5)	86 (8.6)	0.103	40	16	7	4	3	1	5	0	8	9	2	8
6	1717 (9)	177 (10.3)	0.115	125	10	14	7	8	1	1	0	4	1	0	27
8	2937 (15)	424 (14.4)	0.163	342	40	19	7	21	3	4	2	9	4	2	27
10	1400 (7)	200 (14.3)	0.162	158	22	19	0	3	1	4	0	6	1	1	12
13	1101 (7)	146 (13.3)	0.155	123	12	5	3	3	0	2	2	11	4	2	4

Supplementary Table 3. Chromosomal aberrations in descendants of irradiated thymocytes.

Abbreviations: G, gap; B, break; E, exchange; Dic, dicentric; R, ring; F, fragment; DM, double minute; SM, single minute; Pul, pulverization; CF, centromeric fusion.

Weeks after	Mouse	Rearranged sequences	Frequency
irradiation	designation	in thymocyte clones ^a	
0	0w-1	4926·G·16675	7.6 x 10 ⁻⁰
	0w-3	4921·GCTA·16674	7.6 x 10 ⁻⁶
	0w-4	4921·GA·16674	1.3 x 10 ⁻⁵
2	2w-1	8186·CGCGAGGGG·16676	4.4 x 10 ⁻⁶
4	4w-9	4924·G·14786	7.6 x 10 ⁻⁶
8	8w-3	4923·GGTA·16674	1.3 x 10 ⁻⁴
		4923·AGGGG·16674	9.9 x 10 ⁻⁵
		8189·A·16674	4.4 x 10 ⁻⁵
	8w-6	4926·GAGATAC·16676	1.1 x 10 ⁻⁴
		8189·AGGG·16675	1.2 x 10 ⁻⁴
		8190·CA·16674	4.4 x 10 ⁻⁵
	8w-11	4925·GAGGAGT·16676	9.9 x 10 ⁻⁶
	8w-13	8190·GAGGGAA·16675	7.6 x 10 ⁻⁶
		8186·CCC·16676	4.4 x 10 ⁻⁶

Supplementary Table 4. *Notch1* rearrangements in thymocyte clones after 4 consecutive irradiations of 1.8 Gy γ -rays.

^a Rearranged sequences are expressed as breakpoint sequence \cdot inserted nucleotides \cdot breakpoint sequence.

Mice examined	$TCR\beta$ rearrangements in thymocyte clones	Thymic lymphomas examined	$TCR\beta$ rearrangements				
6w-8	a	6w-8-1	D2/J2.3				
		6w-8-2	D2/J2.3				
			D2/GCGGGTA/J2.1				
		6w-8-3	D2/GCGGGTA/J2.1				
8w-14	D2/T/J2.3	8w-14-1	D2/J2.5				
	D2/J2.5	8w-14-2	D2/J2.5				
		8w-14-3	D2/J2.5				
		8w-14-4	D2/T/J2.3				
			D2/J2.5				
8w-16	D1/J1.1	8w-16-1	D1/J1.1				
	D2/T/J2.4		D2/T/J2.4				
		8w-16-2	D1/J1.1				
			D2/T/J2.4				
		8w-16-3	D1/J1.1				
			D2/T/J2.4				
		8w-16-4	D1/J1.1				
			D2/T/J2.4				
		8w-16-6	D1/J1.1				
			D2/T/J2.4				
8w-17	D1/GA/J1.4	8w-17-1	D1/GA/J1.4				
	D2/CGCGGG/J2.2		D2/CGCGGGG/J2.2				
	D2/T/J2.7		D2/T/J2.7				
		8w-17-2	D1/GA/J1.4				
			D2/CGCGGG/J2.2				
			D2/T/J2.7				
		8w-17-3	D1/GA/J1.4				
			D2/CGCGGG/J2.2				
			D2/T/J2.7				
		8w-17-4	D1/GA/J1.4				
			D2/CGCGGG/J2.2				
			D2/T/J2.7				
10w-3	D1/GGAA/J1.4	10w-3-1	D2/TACG/J2.5				
	D2/CGT/J2.3	10w-3-2	D2/TACG/J2.5				
	D2/TACG/J2.5	10w-3-3	D2/TACG/J2.5				
		10w-3-4	D2/TACG/J2.5				
10w-7	D1/CCCCTTCGGG/J1.3	10w-7-1	D1/CCCCTTCGGG/J1.3				
		10w-7-2	D1/CCCCTTCGGG/J1.3				
		10w-7-3	D1/CCCCTTCGGG/J1.3				
		10w-7-4	D1/CCCCTTCGGG/J1.3				

Supplementary Table 5. Examples of $TCR\beta$ rearrangements in thymocyte clones and resultant thymic lymphomas.

^a The minus symbol indicates the absence of clonal *TCR* β rearrangements in thymocytes.

Thymic lymphomas	No. of <i>Notch1</i> rearrangements	Rearranged sequences ^a
6w-7-1	2	4924·G·16675, ?
бw-8-1	4	4925·16676, 8190·T·15582, 8190·16677, 8190·16681
6w-8-2	1	4924.16676
6w-8-3	3	4925.16676, 11179.15437, ?
6w-9-1	1	4926·AA·16675
6w-9-2	1	4926·GGAGG·16675
6w-9-3	5	4926·14781, 4926·GGAC·16675, 4926·GGGA·22145,
		4926·GGGA·22147, 8073·TC·16006
бw-9-4	0	
6w-9-5	2	4923·GTTA·16674, 8073·C·16006
6w-10-2	1	4926·A·16674
6w-10-3	1	? in juxtamembrane extracellular domain
6w-10-4	1	4926.16674
8w-13-1	0	
8w-13-2	2	4926·TGGG·16676, 4926·GGACGGTATATG·16675
8w-13-3	1	4926·GGGGGGG·16676
8w-14-1	1	?
8w-14-2	2	4926·GTG·16676, ?
8w-14-3	1	4926·TGG·16674
8w-14-4	1	4923·T·16674
8w-16-1	1	? in juxtamembrane extracellular domain
8w-16-2	0	
8w-16-3	1	4923·A·16674
8w-16-4	1	? in juxtamembrane extracellular domain
8w-16-6	0	
8w-17-1	5	4923·GTTTTA·22147, 4923·GTTTTA·22149, 4926·GTG·16676,
		4925·GCG.16677, 8185·TG·16676
8w-17-2	7	4926·A·16674, 4925·AAA·22146, 4926·GTT·22146,
		8185·GATCTCT·15809, 8187·CTGA·16674, 8188·CCTA·16674, ?
8w-17-3	5	4926·GGGCAG·16676, 4926·GCC·22149, 8190·T·16009,
		8190·GGG·16676, ?
8w-17-4	1	4924·GGGAG·16675
10w-1-1	1	4923·GCCGCCAG·16675
10w-1-2	2	4921.CCCCCTG.16675, 8190.ATTTTTGCATG.16676
10w-1-4	2	4926·TAGCTTT·16678, ?
10w-1-5	2	4926·GGGAT·16676, ?
10w-3-1	2	?, ?
10w-3-2	2	4921·CTATAA·16677, ?
10w-3-3	3	4925-16677, 8187-GTAAAAG-16674, ?
10w-3-4	1	4926·AGGTA·16674
10w-4-1	2	4922·TA·16674, ?
10w-7-1	1	?
10w-7-2	1	4926 TGGGGATAGG 16676
10w-7-3	0	
10w-7-4	0	

Supplementary Table 6. Rearranged sequences of *Notch1* gene in resultant thymic lymphomas.

^a Rearranged sequences are shown as breakpoint sequence inserted nucleotides breakpoint sequence. The question marks indicate an unknown sequence.